250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotech Startup Investors

A list of 50 angel investors and VC funds that invest in Biotech startups. We rank investors based on the number of investments they made in Biotech companies. This investor list updates every month.

Top 50 Biotech Startup Investors

Investor Biotech investments
ARCH Venture Partners 103
OrbiMed 91
Alexandria Venture Investments 79
Sofinnova Partners 74
New Enterprise Associates 72
Versant Ventures 72
Novo Holdings 70
Innova Memphis 63
MPM Capital 62
F-Prime Capital 62
Atlas Venture 61
5AM Ventures 60
Polaris Partners 57
Khosla Ventures 57
Novartis Venture Fund 56
Third Rock Ventures 55
BioAdvance 49
RA Capital Management 49
M Ventures 47
SR One 45
UK Innovation & Science Seed Fund 45
Bpifrance 44
Fifty Years 44
Takeda Ventures 42
Pfizer Venture Investments 42
Boehringer Ingelheim Venture Fund 42
EQT life science 42
Canaan Partners 42
Sequoia Capital China 41
Parkwalk Advisors 41
Lux Capital 41
Frazier Healthcare Partners 40
Lilly Asia Ventures 40
Connecticut Innovations 40
Sofinnova Investments 39
Seventure Partners 39
High-Tech Grunderfonds 39
Hatteras Venture Partners 39
Casdin Capital 39
DCVC 38
Amgen Ventures 38
Northpond Ventures 37
The Column Group 37
Life Science Angels 36
Andreessen Horowitz 36
Boston Harbor Angels 35
Pontifax 34
Qiming Venture Partners 34
HealthCap 34
Oxford Technology Management 34
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
ARCH Venture Partners VC Fund · Chicago, Illinois, United States · 30 investments in the past 12 months
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, China, Canada
Portfolio highlights
  • Paratus Sciences — Unlocking the secrets of bat biology. We are focused on elucidating novel insights and identifying new therapeutic targets.
  • Aera Therapeutics — Aera Therapeutics is a biotechnology company that uses its proprietary protein nanoparticle (PNP) delivery platform to help genetic medicines reach their full potential. Aera's platform, which is based on endogenous human proteins, is being developed to address the limitations of current delivery technologies and to extend the reach of geneticmedicines to different tissues and applications, thereby benefiting more patients across a broader range of disease areas. In addition, Aera's licensed technology includes a therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.
  • IngredientWerks — IngredientWerks is a company operating in stealth. IngredientWerks was founded in 2022 and is based in Woburn, Massachusetts.
OrbiMed VC Fund · New York, New York, United States · 37 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • TandemAI — TandemAI is focused on lowering the barrier to entry to the most advanced tools in drug discovery.
  • BIOMx — Developing natural and engineered phage therapies to eradicate harmful bacteria in chronic diseases.
  • Garuda Therapeutics — Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.
Alexandria Venture Investments VC Fund · Pasadena, California, United States · 24 investments in the past 12 months
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, France, Canada
Portfolio highlights
  • Paratus Sciences — Unlocking the secrets of bat biology. We are focused on elucidating novel insights and identifying new therapeutic targets.
  • Melonfrost — Melonfrost has created a novel way to optimize strains, eliminating the biggest bottleneck in the bioeconomy. By combining machine learning and evolution, our proprietary AI + Hardware platform steers the evolution of cells in real-time. Our algorithms explore the biological space and make decisions, while innovations in robotics, sensing, fluidicsand environmental control replace scientific labor, shaving years off the time to market for bioproducts. Evolution, from millenia to months.
  • Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Sofinnova Partners VC Fund · Paris, Ile-de-France, France · 13 investments in the past 12 months
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • France, United States, United Kingdom
Portfolio highlights
  • Amolyt Pharma — We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.
  • EnginZyme — EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide.
  • Microphyt — Discover exclusive biomimetic technology that unlocksthe full potential of untapped micro-algae diversity.
New Enterprise Associates VC Fund · Menlo Park, California, United States · 69 investments in the past 12 months
New Enterprise Associates, Inc. is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’slifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series B, Series A, Series C
  • United States, India, China
Portfolio highlights
  • Brale — Combining the best of CeFi & DeFi.
  • Ledge — Ledge is a command center for payments built for finance teams operating at scale.Ledge empowers finance teams with tools to centralize their payments data, get a real-time payments snapshot, automate multi-way reconciliation, identify problem transactions, accelerate their investigations, and dramatically lower the risk of losses, all withoutany engineering support.Finance teams regain control of payments and are freed to focus on strategic business impact, not manual payments work.
  • Flox — Manage and share development environments, package your projects for others, and publish artifacts anywhere. Harness the power of Nix.
Versant Ventures VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Belharra Therapeutics — Belharra Therapeutics is a privately held drug discovery company that is disrupting the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform. Belharra scientists can identify small molecule drug candidates for any binding site, on any protein, in any conformational state, and in any cell type using its chemoproteomicsplatform. Belharra is based in the San Francisco Bay Area, with its primary lab and offices in San Diego.
  • Launchpad Therapeutics — Launchpad Therapeutics operates as an antibody-focused precision oncology company.
  • iECURE — Knocking down devastation. Inserting hope. At iECURE, we believe in vivo gene editing is the answer to meeting this immense patient need, and we believe reversing the course of these conditions is now within reach.
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 23 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • Aquafortus — Aquafortus specializes in providing enviornmental services and commercializes proprietary zero liquid discharge technology.
  • Elo Life Systems — Elo is the Next Generation Ingredient Company. We unlock nature's abilities to make consumers' favorite foods more delicious, healthy and planet friendly.
  • LePure Biotech — Lechun Biology is an enterprise engaged in disposable products and leak detection equipment in the biotechnology and pharmaceutical industries. The company develops and produces disposable biopharmaceutical process equipment and consumables. The products are used for the storage, transportation, filling and leak detection of various samples inbiosimilars, vaccines and other biopharmaceutical processes. The core product is a disposable storage bag. Recently completed B+ round of financing. This round of financing will be mainly used for the development of a number of innovative new products, the establishment of a US R&D center, the integration of the upstream industrial chain, the securing of the supply chain, and the expansion of the R&D market operation team at home and abroad.
Innova Memphis VC Fund · Memphis, Tennessee, United States · 10 investments in the past 12 months
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more
Investment focus
  • Health Care, Science/Engineering, Software
  • Seed, Pre-Seed, Series A
  • United States, Argentina, United Kingdom
Portfolio highlights
  • Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.
  • Isomark Health — Isomark Health is a patented AI-based, real-time and 100% green breath technology that detects and prevents bacterial and viral infections.
  • Stony Creek Colors — Stony Creek Colors is engaged in the production of bio-based dyes together with farmers, mills, and brands, in partnership with small farmers in the Southeast U.S. Stony Creek Colors was founded by Sarah Bellos in 2012 and is based in Tennessee, United States.
MPM Capital VC Fund · Cambridge, Massachusetts, United States · 4 investments in the past 12 months
Powering Breakthroughs in Life Sciences
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • United States, Canada, Germany
Portfolio highlights
  • NextPoint Therapeutics — NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells.
  • Photys Therapeutics — Photys Therapeutics is a proprietary chimeric small molecules platform company, developing a new class of medicines for precise control of protein function.
  • Aktis Oncology — Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care
F-Prime Capital VC Fund · Cambridge, Massachusetts, United States · 33 investments in the past 12 months
We create and invest in healthcare and technology companies that improve lives all over the world.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • NOCD — Reduce OCD severity significantly in just 10 weeks on average. Schedule a FREE phone call with team, and we'll connect you with a licensed OCD Therapist.
  • Enzene Biosciences — We are driven by the vision to positively impact the global healthcare landscape by delivering reliable and affordable medicines to improve life quality.
  • Paradigm — Paradigm is building a platform that enables equitable access to clinical trials while enhancing efficiency and improving ease of use for providers.
Atlas Venture VC Fund · Cambridge, Massachusetts, United States · 7 investments in the past 12 months
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Series C
  • United States, United Kingdom, Germany
Portfolio highlights
  • Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
  • Disc Medicine — We are restoring regulation of hepcidin - the link between genetics and erythropoiesis - to create new therapies for patients with inherited and acquired anemias.
5AM Ventures VC Fund · Menlo Park, California, United States · 6 investments in the past 12 months
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Novome Biotechnologies — Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.
  • Disc Medicine — We are restoring regulation of hepcidin - the link between genetics and erythropoiesis - to create new therapies for patients with inherited and acquired anemias.
  • CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.
Polaris Partners VC Fund · Boston, Massachusetts, United States · 14 investments in the past 12 months
Polaris Partners ​has over 20-year history partnering with ​repeat entrepreneurs and innovators who are improving the way people live and work. The ​multibillion-dollar firm invests in healthcare and technology companies ​across all stages, from founding to profitable growth. ​Polaris has offices in Boston and San Francisco. ​Polaris Partners wasfounded in 1996 and is headquartered in Boston, Massachusetts.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • United States, Singapore, Ireland
Portfolio highlights
  • Paratus Sciences — Unlocking the secrets of bat biology. We are focused on elucidating novel insights and identifying new therapeutic targets.
  • August Bioservices — August Bioservices is a contract development and manufacturing organization (CDMO) providing drug discovery, development, and pharmaceutical manufacturing services. August Bioservices provides comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnologyindustries. PMI BioPharma Solutions is uniquely positioned to support individual projects or to serve as an extension of its customers’ development teams. PMI BioPharma Solutions is planning to scale its manufacturing capabilities to support late-stage clinical and commercial liquid and lyophilized filling demand, to help support projects from clinical development to commercial launch.
  • Jnana Therapeutics — Jnana was founded by leading academic scientists, drug developers and investors to develop medicines that transform the lives of patients.
Khosla Ventures VC Fund · Menlo Park, California, United States · 57 investments in the past 12 months
Khosla Ventures is a venture capital firm started in 2004 by Vinod Khosla, Co-Founder of Sun Microsystems. The firm provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies.With over $15b assets under management, the firm focuses on a range of areas including consumer, enterprise, education,advertising, financial services, semiconductors, health, big data, agriculture, food, sustainable energy, and robotics. Khosla Ventures is headquartered in Menlo Park, California.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series A, Series B, Seed
  • United States, India, United Kingdom
Portfolio highlights
  • Astrus — Astrus fully automates analog layout using AI without disrupting your workflow.
  • Sonocharge Energy — Sonocharge energy is developing a platform technology that enables a battery to charge. This technology energizes a range of markets such as transportation electric vehicles, e-mobility, electric bikes, scooters, aerospace, electric airplane, and drones.
  • Calimero Network — Calimero Network is a blockchain infrastructure that helps clients in controlling data. Calimero Network was founded in 2022 and was headquartered in London.
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 2 investments in the past 12 months
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • Epsilogen — IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Third Rock Ventures VC Fund · Boston, Massachusetts, United States · 5 investments in the past 12 months
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.
  • Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
  • Terremoto Biosciences — By unleashing the power of covalent chemistry, we can deliver superior small molecule medicines with enhanced therapeutic benefit.
BioAdvance VC Fund · Philadelphia, Pennsylvania, United States · 4 investments in the past 12 months
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Seed, Funding Round, Series A
  • United States, Canada
Portfolio highlights
  • Innervace — Innervace is a developer of a regenerative therapy company designed to develop implantable tissue-engineered brain pathways for neurodegenerative disorders.The company is focused on the development and commercialization of anatomically inspired living scaffolds for brain pathway reconstruction, and its lead clinical product is a tissue-engineerednigrostriatal pathway that mimics the lost nigrostriatal pathway in patients with Parkinson's disease. This gives patients access to technology that specifically reconstructs brain pathways rather than just masking symptoms temporarily.Innervace was established in 2018 by in Philadelphia, Pennsylvania
  • Senzo — Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device.
  • Halo Labs — Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics.Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced ResearchProjects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.The company was founded in 2011 and headquartered in Pennsylvania, United States.
RA Capital Management VC Fund · Boston, Massachusetts, United States · 25 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. Their team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. Theyinvest in companies with promising technologies and products. Their approach is to achieve a superior understanding of data, experimental/trial design, regulatory process, and commercial potential. When appropriate, they can offer their portfolio companies leads on in-licensing opportunities and strategic partnerships, as well as insight into the demands of the public markets.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series B, Series A, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Vaxess Technologies — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
  • Vor Biopharma — Protect the healthy cells, expose the cancer - We aim to cure blood cancers through cell and genome engineering
  • Apogee Therapeutics — Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders. The company aims to advance novel therapies to address patients’ needs. Based in San Francisco, California, Apogee Therapeutics was founded in 2022.
M Ventures VC Fund · Amsterdam, Noord-Holland, The Netherlands · 9 investments in the past 12 months
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
  • Storm Therapeutics — Targeting pathways that modify RNA to deliver novel cancer therapeutics.
  • Sonde Health — Sonde Health is a digital medicine company developing voice-based technologies to transform the way we monitor and diagnose our mental and physical health.
SR One VC Fund · Cambridge, Massachusetts, United States · 5 investments in the past 12 months
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Rezo Therapeutics — Rezo Therapeutics identifies targets and therapies by combining distinct, unbiased technologies with artificial intelligence. Rezo's proprietary platform can be used to treat a wide range of diseases. Rezo's initial focus is oncology, with plans to expand into other therapeutic areas through collaborations and partnerships.
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
UK Innovation & Science Seed Fund VC Fund · Harwell, Oxfordshire, United Kingdom · 7 investments in the past 12 months
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Seed, Funding Round, Series A
  • United Kingdom, United States
Portfolio highlights
  • Vector Photonics — Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.
  • MicrofluidX — Delivering the next generation of automated cell and gene therapy manufacturing platforms to bring precision medicine to patients
  • Silveray — Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.
Bpifrance VC Fund · Maisons-alfort, Ile-de-France, France · 95 investments in the past 12 months
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Funding Round, Seed, Series A
  • France, United States, Canada
Portfolio highlights
  • Locuta — Locuta specializes in callbots for call centers and commercial services.
  • NFL Biosciences — NFL Biosciences is a biotechnology company developing naturally based addiction withdrawal solutions. Its core product NFL-101, now in Phase II clinical trial aims to help smokers willing to quit win their battle for a healthier life.
  • Previa Medical — Previa Medical analyzes the data of the patients in real time and identifies the complication risks. They also provide forecasting pathology. They use FHIR technology for their solutions. The company's contact modes are by mail and physical address.
Fifty Years VC Fund · San Francisco, California, United States · 15 investments in the past 12 months
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Seed, Series A, Series B
  • United States, Germany, Canada
Portfolio highlights
  • Journey Clinical — Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
  • UTVATE — Unlocking satellite internet capacity through user terminal innovation
  • BillionToOne — We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward.
Takeda Ventures VC Fund · San Diego, California, United States · 7 investments in the past 12 months
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A, Series B, Funding Round
  • United States, United Kingdom, Japan
Portfolio highlights
  • Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
  • Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
  • hC Bioscience — hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
Pfizer Venture Investments VC Fund · New York, New York, United States · 13 investments in the past 12 months
Pfizer Venture Investments is a venture capital firm.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series B, Series A, Series C
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.
  • Storm Therapeutics — Targeting pathways that modify RNA to deliver novel cancer therapeutics.
  • Nucleome Therapeutics — Decoding the dark matter of the human genome to deliver first-in-class precision medicinesDiscover More
Boehringer Ingelheim Venture Fund VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 4 investments in the past 12 months
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, Germany, Belgium
Portfolio highlights
  • Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
  • Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
  • C-mo Medical Solutions — C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.
EQT life science VC Fund · Amsterdam, Noord-Holland, The Netherlands · 3 investments in the past 12 months
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example,LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, The Netherlands, Switzerland
Portfolio highlights
  • eTheRNA immunotherapies — eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases.
  • ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
  • Ariceum Therapeutics — Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Canaan Partners VC Fund · Menlo Park, California, United States · 21 investments in the past 12 months
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series A, Series B, Series C
  • United States, Israel, United Kingdom
Portfolio highlights
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.
  • Komprise — Save on data storage costs with Komprise Intelligent Data Management, the leader in unstructured data management and cloud file data migration. Analyze. Mobilize.
  • Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
Sequoia Capital China VC Fund · Beijing, Beijing, China · 94 investments in the past 12 months
We help founders build enduring companies.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series A, Series B, Series C
  • China, United States, Hong Kong
Portfolio highlights
  • NOWCODER — NOWCODER develops a written test and interview database platform for IT programmers.
  • Danking Pharmaceuticals — Danking Medicine is an innovation-driven drug developer.
  • MoleculeMind — MoleculeMind is an AI-integrated biotech firm that fuses artificial intelligence with biotechnology to form a new development platform.
Parkwalk Advisors VC Fund · London, England, United Kingdom · 17 investments in the past 12 months
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more
Investment focus
  • Science/Engineering, Health Care, Software
  • Seed, Series A, Series B
  • United Kingdom, United States, Philippines
Portfolio highlights
  • Quantum Motion — One Hundred Qubits is Interesting. One Million is World-changing
  • Qkine — Growth Factors made for stem cells Animal-free We control every step of protein manufacture ensuring all our products are completely animal-free Total transparency Stringent purity and bioactivity testing data for all proteins - know what you are giving your cells Protein innovation Our R&D team
  • Diffblue — Diffblue helps accelerate your shift left by automatically writing suites of unit regression tests so you can catch errors faster and earlier in your pipeline
Lux Capital VC Fund · New York, New York, United States · 51 investments in the past 12 months
Lux Capital Management manages of $4 billion in assets focused on founding, seed, early-stage, and growth investments in the physical, material and life sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures our portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series A, Seed, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Aera Therapeutics — Aera Therapeutics is a biotechnology company that uses its proprietary protein nanoparticle (PNP) delivery platform to help genetic medicines reach their full potential. Aera's platform, which is based on endogenous human proteins, is being developed to address the limitations of current delivery technologies and to extend the reach of geneticmedicines to different tissues and applications, thereby benefiting more patients across a broader range of disease areas. In addition, Aera's licensed technology includes a therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.
  • Thatch — Thatch makes paying for healthcare easier and more modern. Our mission is to help businesses give great healthcare to their employees.
  • VulnCheck — Vulnerability intelligence that predicts avenues of attack with speed and accuracy.
Frazier Healthcare Partners VC Fund · Seattle, Washington, United States
Frazier Healthcare Partners: Investing exclusively in healthcare for 25 years.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Post-IPO Equity
  • United States, Canada, Ireland
Portfolio highlights
  • New Amsterdam Pharma — NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
  • Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
  • Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
Lilly Asia Ventures VC Fund · Shanghai, Shanghai, China · 11 investments in the past 12 months
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • China, United States, Hong Kong
Portfolio highlights
  • Yinghe Brain Science — Yinghe Brain Science is a neuromodulation platform developer
  • ADARx Pharmaceuticals — ADARx is a genetic medicine company focusing on the editing of Messenger RNA Targeting transcripts and oligonucleotide-based therapeutics.
  • Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
Connecticut Innovations VC Fund · Rocky Hill, Connecticut, United States · 15 investments in the past 12 months
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
  • Health Care, Science/Engineering, Software
  • Seed, Series A, Funding Round
  • United States, Israel, Canada
Portfolio highlights
  • ReferWell — ReferWell leverages the referable moment to transform, simplify and integrate healthcare delivery so more people get the care they need.
  • Torigen Pharmaceuticals — Torigen is leading the pack in vet pharmaceuticals and oncology. Our tissue vaccine uses the tumor to create a personalized immunotherapy for treatment of cancer in both exotic and companion animals. We recognize the instrumental role animals play in society and our families, and are determined to
  • Bags — Grow your business with access to fair and flexible funding options designed to help you do your thing. Bags is the best place for business owners to get dollars for working capital, inventory, marketing, expansion, or anything else you need to grow.
Sofinnova Investments VC Fund · Menlo Park, California, United States · 2 investments in the past 12 months
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • United States, France, United Kingdom
Portfolio highlights
  • immatics biotechnologies — immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche.
  • RayzeBio — Defeating cancer withradiopharmaceuticalmedicines
  • NorthSea Therapeutics — NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Seventure Partners VC Fund · Paris, Ile-de-France, France · 9 investments in the past 12 months
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Funding Round
  • France, United States, Germany
Portfolio highlights
  • Ervaccine Technologies — Ervaccine Technologies a developer of next-generation cancer vaccines that targets endogenous retroviruses.
  • Clinical Microbiomics — Expert microbiome analysis services, including for gut, oral, skin, and for pre clinical & clinical trials.
  • Standing Ovation — Animal-free dairy cheese
High-Tech Grunderfonds VC Fund · Bonn, Nordrhein-Westfalen, Germany · 45 investments in the past 12 months
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Seed, Series A, Funding Round
  • Germany, Switzerland, United States
Portfolio highlights
  • hbox — We are developing therapies based on the principle of minimally invasive targeted hyperoxygenation.
  • Sdui — Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market.
  • Maya Climate — Accelerating investments in early-stage nature-based carbon projects, by connecting project developers with commercial investors on a single platform that digitizes project origination, risk assessment and due diligence.
Hatteras Venture Partners VC Fund · Durham, North Carolina, United States · 5 investments in the past 12 months
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Funding Round
  • United States, Canada
Portfolio highlights
  • Cardiosense — Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
  • Boomerang Medical — Boomerang Medical is a bioelectronic medicine company targeting autoimmune diseases.
  • RapidPulse — RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
Casdin Capital VC Fund · New York, New York, United States · 21 investments in the past 12 months
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series B, Series A, Series C
  • United States, France, China
Portfolio highlights
  • Chroma Medicine — Chroma Medicine is pioneering a new class of epigenetic medicines to revolutionize treatment of genetically driven disease.
  • iVexSol — iVexSol is a newly formed viral vector manufacturing company
  • Nest Genomics (YC W22) — Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale.
DCVC VC Fund · San Francisco, California, United States · 23 investments in the past 12 months
Deep Tech VC firm with over $3B under management
Show more
Investment focus
  • Software, Science/Engineering, Data and Analytics
  • Seed, Series A, Series B
  • United States, Canada, Australia
Portfolio highlights
  • Aquafortus — Aquafortus specializes in providing enviornmental services and commercializes proprietary zero liquid discharge technology.
  • Nest Genomics (YC W22) — Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale.
  • Reach — Founded out of MIT, Reach Labs is deeply rooted in technology and design. Their mission is to empower the world with seamless connectivity.
Amgen Ventures VC Fund · San Francisco, California, United States · 11 investments in the past 12 months
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series B, Series A, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
  • Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
  • ImmunoScape — ImmuniScape discovers and develops novel TCR-based therapeutics against solid tumors
Northpond Ventures VC Fund · Bethesda, Maryland, United States · 14 investments in the past 12 months
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, United Kingdom, Australia
Portfolio highlights
  • Sound Agriculture — Sound Agriculture is creating a more agile and resilient food system with innovative on-demand crop solutions.
  • EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
  • Vestaron — Are you interested in biological peptides? If so, get in contact with Vestaron today. We will keep you informed about safer crop protection.
The Column Group VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Show more
Investment focus
  • Biotechnology, Science/Engineering, Health Care
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Synthekine — Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.
  • Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
  • Escient Pharmaceuticals — We apply state-of-the-art medicinal chemistry and biological tools to develop targeted small molecule therapeutics that hold potential to become novel, highly differentiated treatment options for a broad range of diseases.
Life Science Angels VC Fund · Sunnyvale, California, United States · 2 investments in the past 12 months
Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Funding Round, Seed, Series A
  • United States, Israel, The Netherlands
Portfolio highlights
  • Avisi Technologies — Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.
  • InnoSIGN — We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
  • Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Andreessen Horowitz VC Fund · Menlo Park, California, United States · 179 investments in the past 12 months
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, that backs bold entrepreneurs building the future through technology.
Show more
Investment focus
  • Software, Internet, Financial
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • Shef — Enter code FIRST10 at checkout and save $10 on your first order
  • Zarta — Zarta is an ad free, micro pay per view video platform, and our mission is to connect creators directly to their community.
  • Skydio — Skydio Autonomous Drones for business, public safety and creative endeavors.
Boston Harbor Angels VC Fund · Boston, Massachusetts, United States
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Angel, Seed, Series A
  • United States, Canada, India
Portfolio highlights
  • Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
  • Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
  • Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Pontifax VC Fund · Herzliya, Tel Aviv, Israel
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, Israel, France
Portfolio highlights
  • Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
  • ARMGO,Pharma,Inc. — ARMGO Pharma, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. It offers rycals, which are calcium release channel stabilizers that act on ryanodine receptor/calcium release channel, a therapeutic target located on thesarcoplasmic/endoplasmic reticulum of the cell for treating chronic heart failure, cardiac arrythmias, and muscle disorders, as well as cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. The company was incorporated in 2004 and is based in Tarrytown, New York with an additional office in New York, New York.
  • Anaveon — Anaveon is a biopharmaceutical company that transforms engineered cytokines into novel life-saving treatments. The first program going into clinical trials is a selective IL-2 receptor agonist.
Qiming Venture Partners VC Fund · Shanghai, Shanghai, China · 40 investments in the past 12 months
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have investedin outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.
Show more
Investment focus
  • Health Care, Science/Engineering, Software
  • Series B, Series A, Series C
  • China, United States, Hong Kong
Portfolio highlights
  • Hochuen Medical Technology — Hochuen Medical was founded in 2015 by Dr. Robin Liu, an entrepreneur in IVD medical and microfluidics fields, and Eric Zeng, an expert in the electronics OEM industry. The founding management team has an average of more than 20 years of management experience in manufacturing of microfluidic devices, medical disposables, and consumer electronicproducts. Dr. Robin Liu, co-founder and president of Hochuen Medical, has more than 20 years of experience in the IVD and microfluidic industry, with experience at Motorola, CombiMatrix, GenMark, Beckman Coulter/Danaher, etc. Dr. Liu brings both experience in R&D and production management in the fields of molecular diagnosis, immunoassays, hematology, urinalysis, etc
  • Tingsheng Technology — TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digitalheart model.
  • Yike Polymers — Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
HealthCap VC Fund · Stockholm, Stockholms Lan, Sweden · 3 investments in the past 12 months
HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with the Odlander Fredrikson Group as their exclusive investments advisor. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized provider of venture capital within life sciences Europe.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series B, Series A, Funding Round
  • United States, Sweden, France
Portfolio highlights
  • Ariceum Therapeutics — Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
  • Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
  • HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
Oxford Technology Management VC Fund · Oxford, Oxfordshire, United Kingdom
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Seed, Funding Round, Series A
  • United Kingdom, United States
Portfolio highlights
  • MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
  • OxCan — Enabling curative cancer treatment through early detection
  • Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
Investors by industry
Investors by country
Investors in Biotech by country
Angel investors in Biotech by country
VC Funds in Biotech by country